Breaking News Instant updates and real-time market news.

TSRO

TESARO

$145.90

-1.34 (-0.91%)

05:28
01/12/17
01/12
05:28
01/12/17
05:28

TESARO receives CRL from FDA for rolapitant IV NDA

TESARO announced that the FDA has issued a Complete Response Letter, or CRL, regarding the rolapitant IV New Drug Application, or NDA, for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. FDA requested additional information regarding the in vitro method utilized to demonstrate comparability of drug product produced at the two proposed commercial manufacturers for rolapitant IV that were included in the NDA. TESARO is working expeditiously to provide the requested information. The CRL did not identify concerns related to the safety or efficacy of rolapitant IV or request additional clinical studies. No concerns were raised regarding the active pharmaceutical ingredient, which is also used for the Varub oral product. TESARO identified potential deficiencies at the original contract manufacturer for rolapitant IV drug product, secured a second drug product supplier and included data from this manufacturer in the NDA. During the NDA review, FDA requested and TESARO provided in vitro data to demonstrate comparability of drug product made at the two manufacturing sites.

  • 30

    Jun

TSRO TESARO
$145.90

-1.34 (-0.91%)

12/27/16
FBRC
12/27/16
NO CHANGE
Target $151
FBRC
Outperform
FBR Capital ups TESARO price target to $151
FBR Capital analyst Ed White raised his price target for TESARO to $151 from $133 and keeps the Outperform rating on the shares. The oncology-focused biopharmaceutical company closed Friday up $7.27 to $139.86. TESARO recently announced that the FDA has granted Priority Review for niraparib with a June 30, 2017 action date, White tells investors in a research note. He believes niraparib could be a potential blockbuster PARP inhibitor. Meanwhile, the launch of Varubi continues to "ramp up," with sequential quarter-over-quarter unit growth of 14%, the analyst writes. White says the drug achieved a 28% share of the oral NK-1 market in the U.S. in September.
01/04/17
GABE
01/04/17
NO CHANGE
GABE
Gabelli sees Incyte as more likely target following Gilead hire
Gilead (GILD) is more likely to buy Incyte (INCY) after naming Alessandro Riva to head its Hematology and Oncology Therapeutic unit, Gabelli analyst Jing He tells investors in a research note. Dr. Riva is a Novartis (NVS) veteran while Incyte is led by a team of Novartis veterans and has collaborated with Novartis Oncology on its key drug, Jakafi, the analyst points out. He believes Incyte is "big enough to move the needle" and bring long term growth to Gilead. The analyst lists Seattle Genetics (SGEN) and TESARO (TSRO) as other potential targets for the biotech giant. He believes Incyte is the "best fit."
01/09/17
LEER
01/09/17
NO CHANGE
Target $152
LEER
Outperform
TESARO price target raised to $152 from $115 at Leerink
Leerink analyst Seamus Fernandez raised his price target for TESARO to $152 from $115 to fully incorporate his high expectations for a broad label and reflect niraparib's transformation to a commercial stage asset. The analyst notes that the "strong data" from niraparib's NOVA trial, along with the lack of an expected FDA panel, should result in a broad label in the second-line or greater ovarian cancer maintenance setting, while ongoing niraparib trials in breast cancer and front-line ovarian cancer maintenance and the company's IO platform should be additional potential drivers of upside for the stock. Fernandez sees TESARO as an "attractive takeout target," and reiterates an Outperform rating on the shares.
01/10/17
LEER
01/10/17
NO CHANGE
LEER
Outperform
ARIAD acquisition supports potential takeout premium for TESARO, says Leerink
Leerink analyst Seamus Fernandez says the acquisition of ARIAD (ARIA) by Takeda (TKPYY) for $24 per share appears to be relatively in-line with other commercial stage acquisitions, and supports a potential acquisition price for TESARO (TSRO) of greater than $170 per share based on consensus forecasts. While TESARO remains well positioned to grow independently, the analyst believes a validated PARP inhibitor like niraparib could offer a durable and strategically important product opportunity for multiple suitors. He reiterates an Outperform rating on TESARO's shares.

TODAY'S FREE FLY STORIES

04:55
01/21/17
01/21
04:55
01/21/17
04:55
Conference/Events
Peters & Co. hold a conference »

Limited Energy Conference…

ETFC

E-Trade

$36.39

0.15 (0.41%)

04:55
01/21/17
01/21
04:55
01/21/17
04:55
Conference/Events
E*Trade to hold education day »

E*Trade's Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

AMGN

Amgen

$154.67

0.87 (0.57%)

, BAYRY

Bayer

$109.31

0.98 (0.90%)

04:55
01/21/17
01/21
04:55
01/21/17
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2017 Gastrointestinal…

AMGN

Amgen

$154.67

0.87 (0.57%)

BAYRY

Bayer

$109.31

0.98 (0.90%)

BMY

Bristol-Myers

$49.23

-6.26 (-11.28%)

CCXI

ChemoCentryx

$7.56

-0.32 (-4.06%)

CELG

Celgene

$112.66

-0.96 (-0.84%)

DNA

Bought by RHHBY

EXEL

Exelixis

$17.92

0.02 (0.11%)

HALO

Halozyme

$11.50

0.42 (3.79%)

LXRX

Lexicon

$13.84

-0.19 (-1.35%)

MACK

Merrimack

$3.00

-0.05 (-1.64%)

MRK

Merck

$62.53

2.2 (3.65%)

NVS

Novartis

$70.65

0.22 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 26

    Jan

  • 26

    Jan

  • 01

    Feb

  • 02

    Feb

  • 12

    Feb

  • 16

    Feb

  • 21

    Feb

  • 23

    Feb

  • 24

    Feb

  • 28

    Feb

  • 02

    Mar

  • 08

    Mar

  • 15

    Mar

  • 10

    May

  • 27

    May

  • 19

    Jul

KATE

Kate Spade

$17.76

-0.07 (-0.39%)

, COH

Coach

$35.31

0.21 (0.60%)

18:54
01/20/17
01/20
18:54
01/20/17
18:54
Periodicals
Kate Spade draws interest from Coach, Michael Kors, Bloomberg reports »

Kate Spade (KATE) is…

KATE

Kate Spade

$17.76

-0.07 (-0.39%)

COH

Coach

$35.31

0.21 (0.60%)

KORS

Michael Kors

$42.46

0.43 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

CTIC

CTI BioPharma

$4.97

-0.1 (-1.97%)

18:14
01/20/17
01/20
18:14
01/20/17
18:14
Hot Stocks
CTI BioPharma regains compliance with Nasdaq Listing Rule »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$40.46

0.06 (0.15%)

18:06
01/20/17
01/20
18:06
01/20/17
18:06
Hot Stocks
Abbott sponsored study shows SCS therapy can reduce, stabilize opioid use »

New research has found…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 21

    Feb

WMT

Wal-Mart

$67.18

-0.44 (-0.65%)

18:02
01/20/17
01/20
18:02
01/20/17
18:02
Periodicals
Wal-Mart begins corporate job cuts at headquarters, WSJ reports »

Wal-Mart has started on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$35.31

0.21 (0.60%)

, KORS

Michael Kors

$42.46

0.43 (1.02%)

17:46
01/20/17
01/20
17:46
01/20/17
17:46
Periodicals
Breaking Periodicals news story on Coach, Michael Kors, Kate Spade »

Coach, Michael Kors to…

COH

Coach

$35.31

0.21 (0.60%)

KORS

Michael Kors

$42.46

0.43 (1.02%)

KATE

Kate Spade

$17.76

-0.07 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

BELFB

Bel Fuse

$31.80

0.2 (0.63%)

17:33
01/20/17
01/20
17:33
01/20/17
17:33
Hot Stocks
Gabelli reports 23.15% stake in Bel Fuse »

GAMCO, pursuant to Rule…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMD

ResMed

$63.65

0.75 (1.19%)

17:32
01/20/17
01/20
17:32
01/20/17
17:32
Hot Stocks
ResMed, BMC, 3B Medical settle global litigation »

ResMed, BMC, and 3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$3.50

0.05 (1.45%)

17:27
01/20/17
01/20
17:27
01/20/17
17:27
Hot Stocks
Breaking Hot Stocks news story on Northern Oil and Gas »

Elliott Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

$4.06

0.01 (0.25%)

17:12
01/20/17
01/20
17:12
01/20/17
17:12
Hot Stocks
Baytex Energy closes Peace River acquisition »

Baytex Energy closed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FGEN

FibroGen

$25.60

1 (4.07%)

17:09
01/20/17
01/20
17:09
01/20/17
17:09
Hot Stocks
FibroGen 'encouraged' by updated pamrevlumab clinical data »

FibroGen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIPR

Innovative Industrial Properties

$18.86

-0.199 (-1.04%)

17:03
01/20/17
01/20
17:03
01/20/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Innovative Industrial Properties »

Alan D. Gold raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SITE

SiteOne Landscape

$37.26

0.41 (1.11%)

17:03
01/20/17
01/20
17:03
01/20/17
17:03
Hot Stocks
SiteOne Landscape acquires Aspen Valley Landscape Supply »

SiteOne Landscape…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITCB

Itau Corpbanca

$12.55

-0.08 (-0.63%)

17:01
01/20/17
01/20
17:01
01/20/17
17:01
Hot Stocks
Itau Corpbanca files Material Event Notice »

Itau Corpbanca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$232.20

0.79 (0.34%)

16:50
01/20/17
01/20
16:50
01/20/17
16:50
Hot Stocks
Goldman Sachs chief accounting officer Smith to become global head of compliance »

Goldman Sachs said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DAVIDsTEA

$6.65

0.1 (1.53%)

16:47
01/20/17
01/20
16:47
01/20/17
16:47
Hot Stocks
DAVIDsTEA announces two leadership departures »

DAVIDsTEA's Chief HR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$67.18

-0.44 (-0.65%)

, BAYRY

Bayer

$109.31

0.98 (0.90%)

16:47
01/20/17
01/20
16:47
01/20/17
16:47
General news
On The Fly: Stocks end week mixed as Trump takes office »

Stocks ended the week…

WMT

Wal-Mart

$67.18

-0.44 (-0.65%)

BAYRY

Bayer

$109.31

0.98 (0.90%)

GM

General Motors

$37.01

-0.29 (-0.78%)

NFLX

Netflix

$138.60

0.19 (0.14%)

XOM

Exxon Mobil

$85.89

1.16 (1.37%)

JCP

J.C. Penney

$6.85

0.16 (2.39%)

NKE

Nike

$53.20

0.27 (0.51%)

CSX

CSX

$44.33

-1.18 (-2.59%)

CP

Canadian Pacific

$150.99

0.68 (0.45%)

FWP

Forward Pharma

$30.76

2.01 (6.99%)

CWEI

Clayton Williams

$146.85

-1.18 (-0.80%)

NBL

Noble Energy

$40.21

-0.06 (-0.15%)

RAI

Reynolds American

$58.71

0.13 (0.22%)

BTI

British American Tobacco

$117.30

0.54 (0.46%)

LLY

Eli Lilly

$76.81

-0.03 (-0.04%)

CLCD

CoLucid Pharmaceuticals

$46.25

-0.05 (-0.11%)

WBA

Walgreens Boots Alliance

$81.72

-1.77 (-2.12%)

RAD

Rite Aid

$7.46

-1.14 (-13.26%)

TGT

Target

$64.10

-1.29 (-1.97%)

GIMO

Gigamon

$34.20

1.35 (4.11%)

PSO

Pearson

FAST

Fastenal

$51.24

0.69 (1.37%)

CHKP

Check Point

$97.79

1.45 (1.51%)

PG

Procter & Gamble

$87.45

2.75 (3.25%)

IBM

IBM

$170.55

3.74 (2.24%)

SWKS

Skyworks

$88.67

10.21 (13.01%)

MS

Morgan Stanley

$42.59

0.14 (0.33%)

PRGS

Progress Software

$28.18

0.16 (0.57%)

CMA

Comerica

$66.96

0.65 (0.98%)

UNH

UnitedHealth

$158.66

-0.04 (-0.03%)

GS

Goldman Sachs

$232.20

0.79 (0.34%)

C

Citi

$56.11

-0.55 (-0.97%)

RCII

Rent-A-Center

$8.40

0.09 (1.08%)

GE

General Electric

$30.53

-0.68 (-2.18%)

AXP

American Express

$76.20

-0.49 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 20

    Jan

  • 24

    Jan

  • 26

    Jan

  • 26

    Jan

  • 31

    Jan

  • 02

    Feb

  • 07

    Feb

  • 13

    Feb

  • 14

    Feb

  • 14

    Feb

  • 16

    Feb

  • 20

    Feb

  • 21

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 19

    Apr

TSO

Tesoro

$80.48

-0.08 (-0.10%)

16:42
01/20/17
01/20
16:42
01/20/17
16:42
Hot Stocks
Breaking Hot Stocks news story on Tesoro »

Point72 Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$42.59

0.14 (0.33%)

, OIBR

Oi S.A.

16:40
01/20/17
01/20
16:40
01/20/17
16:40
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Oi S.A.  »

Morgan Stanley reports 5%…

MS

Morgan Stanley

$42.59

0.14 (0.33%)

OIBR

Oi S.A.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMH

UMH Properties

16:36
01/20/17
01/20
16:36
01/20/17
16:36
Hot Stocks
UMH Properties closes acquisition of two Ohio communities for about $9.6M »

UMH Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOP

Bioptix

$3.43

0.01 (0.29%)

16:36
01/20/17
01/20
16:36
01/20/17
16:36
Hot Stocks
Bioptix announces workforce reductions »

Bioptix adopted a plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$115.60

0.02 (0.02%)

16:35
01/20/17
01/20
16:35
01/20/17
16:35
Hot Stocks
Court rejects attempt to enforce Ecuadorian judgment against Chevron unit »

A Canadian court has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 23

    Mar

MIME

Mimecast

$21.42

-0.95 (-4.25%)

16:34
01/20/17
01/20
16:34
01/20/17
16:34
Syndicate
Breaking Syndicate news story on Mimecast »

Mimecast files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

  • 13

    Feb

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.